Every clinical and regulatory claim on GLP-1 Cost Guide traces to a primary source. The core references:

Clinical trials

• SURMOUNT-1 — Tirzepatide for obesity — Jastreboff AM, et al. NEJM 2022
• STEP-1 — Semaglutide 2.4 mg for obesity — Wilding JPH, et al. NEJM 2021
• SURPASS-2 — Tirzepatide vs semaglutide — Frías JP, et al. NEJM 2021
• SELECT — Semaglutide cardiovascular outcomes — Lincoff AM, et al. NEJM 2023

Regulatory

• FDA — Compounding policy as GLP-1 supply stabilizes — U.S. Food and Drug Administration
• FDA — Human drug compounding Q&A — U.S. Food and Drug Administration

Pricing figures are recorded from each provider's public pricing page with a "last checked" date; see the price database and methodology.